Aggregate net sales and payment information: August 2025
Published 25 September 2025
© Crown copyright 2025
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/voluntary-scheme-aggregate-net-sales-and-payment-information-august-2025/aggregate-net-sales-and-payment-information-august-2025
Measured sales as of August 2025
Table 1A: 2023 measured sales reported under the 2019 voluntary scheme, statutory scheme and IQVIA data (parallel imports)
| Period | 2019 voluntary scheme (£million) | Statutory scheme (£million) | Parallel imports (£million) | Total (£million) |
|---|---|---|---|---|
| 2023 (annual) | 12,548 | 658 | 668 | 13,874 |
Table 1B: 2024 measured sales reported under the 2024 voluntary scheme, statutory scheme and IQVIA data (parallel imports) for quarter 1 2024 (January to March 2024)
| Period | 2024 voluntary scheme (£million) | Statutory scheme (£million) | Parallel imports (£million) | Total (£million) |
|---|---|---|---|---|
| Jan to Mar 2024 (quarter 1) | 3,345 | 64 | 159 | 3,568 |
Table 1C: 2024 measured sales reported under the 2024 voluntary scheme, statutory scheme and IQVIA data (parallel imports) for quarter 2 to quarter 4 2024 (April to December 2024)
| Period | 2024 voluntary scheme: newer presentations (£million) | 2024 voluntary scheme: older presentations (£million) | Statutory scheme (£million) | Parallel imports (£million) | Total (£million) |
|---|---|---|---|---|---|
| Apr to Jun 2024 (quarter 2) | 2,183 | 1,273 | 62 | 153 | 3,670 |
| Jul to Sep 2024 (quarter 3) | 2,368 | 1,309 | 58 | 164 | 3,898 |
| Oct to Dec 2024 (quarter 4) | 2,253 | 1,367 | 55 | 171 | 3,846 |
Table 1D: 2025 measured sales reported under the 2024 voluntary scheme, statutory scheme and IQVIA data (parallel imports) for January to June 2025 onwards
| Period | 2024 voluntary scheme: newer presentations (£million) | 2024 voluntary scheme: older presentations (£million) | Statutory scheme: newer presentations (£million) | Statutory scheme: older presentations (£million) | Parallel imports (£million) | Total (£million) |
|---|---|---|---|---|---|---|
| Jan to Mar 2025 (quarter 1) | 2,130 | 1,277 | 6 | 51 | 171 | 3,636 |
| Apr to Jun (quarter 2) | 2,260 | 1,287 | 8 | 54 | 180 | 3,789 |
Tables 1A, 1B, 1C and 1D notes:
- Tables 1A, 1B, 1C and 1D set out aggregate information to date for calendar years 2023, 2024 and 2025 about measured sales subject to the affordability mechanism. This includes information received on parallel imports from IQVIA adjusted to net prices, and information from audited annual sales reports and unaudited quarterly sales reports provided by members of the 2019 and 2024 voluntary schemes and the statutory scheme.
- The baseline for measured sales in respect of the 2024 voluntary scheme, statutory scheme and parallel imports has been calculated in accordance with annex 4 of the 2024 voluntary scheme.
- ‘Measured sales’ is defined in the glossary of the 2024 voluntary scheme for branded medicines pricing, access and growth (VPAG) as “sales of scheme products by scheme members, statutory scheme sales and parallel import sales, but excluding exemptions from measured sales”.
- Annual figures for the 2024 voluntary scheme and the statutory scheme reflect any audited sales reports received.
- Measured sales in any particular period reflects all relevant scheme members in either the 2024 voluntary scheme or statutory scheme during that period. For example, if a company moves from the statutory scheme to the voluntary scheme at the start of a calendar year, that company’s measured sales will appear under the statutory scheme in the year it was covered by the Branded Health Service Medicines (Costs) Regulations 2018, but the voluntary scheme in the year it joined VPAG.
- For VPAG, quarter 1 2024 was a transition period, therefore the data for this quarter was provided at the aggregate level only. For the statutory scheme, the affordability mechanism was not split by newer and older medicines in quarter 1 to quarter 4 2024 and, therefore, the data for this period was provided at the aggregate level only.
2024 voluntary scheme: eligible sales, resulting total scheme payments and payment element relating to VPAG investment programme
Table 2A: 2024 voluntary scheme - eligible sales, resulting total scheme payments, excluding the annual older medicines top-up payments, and payment element relating to VPAG investment programme
| Period | Voluntary scheme aggregate eligible sales (£million) | Resulting aggregate scheme payments, excluding annual older medicines top-up payments (£million) | Element of aggregate scheme payment relating to VPAG investment programme (£million) |
|---|---|---|---|
| Jan to Mar 2024 | 3,047 | 594 | 1 |
| Apr to Jun 2024 | 3,256 | 430 | 1 |
| Jul to Sep 2024 | 3,501 | 463 | 1 |
| Oct to Dec 2024 | 3,430 | 449 | 1 |
| Jan to Mar 2025 | 3,003 | 542 | 18 |
| Apr to Jun 2025 | 3,190 | 580 | 19 |
Table 2B: 2024 voluntary scheme - eligible sales of newer medicines and resulting scheme payments
| Period | Voluntary scheme aggregate eligible sales: newer medicines (£million) | Resulting voluntary scheme aggregate scheme payments: newer medicines (£million) |
|---|---|---|
| Apr to Jun 2024 | 2,039 | 308 |
| Jul to Sep 2024 | 2,218 | 335 |
| Oct to Dec 2024 | 2,081 | 314 |
| Jan to Mar 2025 | 1,874 | 429 |
| Apr to Jun 2025 | 2,020 | 463 |
Table 2C: 2024 voluntary scheme - eligible sales for older medicines and resulting scheme payments, excluding annual top-up payments
| Period | Voluntary scheme aggregate eligible sales: older medicines (£million) | Resulting voluntary scheme, excluding annual top-up payments (£million) |
|---|---|---|
| Apr to Jun 2024 | 1,217 | 122 |
| Jul to Sep 2024 | 1,283 | 129 |
| Oct to Dec 2024 | 1,349 | 135 |
| Jan to Mar 2025 | 1,129 | 113 |
| Apr to Jun 2025 | 1,170 | 117 |
Tables 2A, 2B and 2C notes:
- Tables 2A, 2B and 2C, which are derived from unaudited quarterly sales reports and any audited annual sales reports received from members of the 2024 voluntary scheme, set out aggregate information showing eligible sales covered by the scheme payment and the resulting scheme payments. Table 2A also reports the element of the total aggregate payment relating to the VPAG investment programme.
- ‘Eligible sales’ is defined in the glossary of the 2024 voluntary scheme as “sales of scheme products by scheme members but excluding exemptions from eligible sales”. The relevant percentage payments apply to these sales. Eligible sales exclude certain types of sales, including the first £6 million of sales by a medium-sized company and new active substance (NAS) sales. Both of these sales categories are, however, included in measured sales and, therefore, the calculation of the overall sum to be repaid across all scheme members.
- Table 2B reports aggregate and resulting payments generated by the headline payment percentage for the relevant period. Table 2C reports aggregate eligible sales and resulting payments generated by the basic payment percentage for quarterly periods and the basic payment percentage plus the calculated top-up payment percentages for annual periods.
- Pending resubmission of data reflecting its change in status, dapagliflozin sales continue to be counted under the newer medicine classification.
Statutory scheme: eligible sales and resulting payments
Table 3A: statutory scheme - eligible sales and resulting total scheme payments, excluding the annual older medicines top-up payments, 2023 onwards
| Period | Statutory scheme aggregate eligible sales (£million) | Total statutory scheme payment (£million) |
|---|---|---|
| 2023 (annual) | 658 | 182 |
| Jan to Mar 2024 | 63 | 14 |
| Apr to Jun 2024 | 60 | 13 |
| Jul to Sep 2024 | 58 | 13 |
| 2024 (annual) | 235 | 52 |
| Jan to Mar 2025 | 57 | 6 |
| Apr to Jun 2025 | 61 | 7 |
Table 3B: statutory scheme - eligible sales of newer medicines and resulting scheme payments
| Period | Aggregate statutory scheme eligible sales: newer medicines (£million) | Resulting aggregate statutory scheme payments: newer medicines (£million) |
|---|---|---|
| Jan to Mar 2025 | 6 | 1 |
| Apr to Jun 2025 | 7 | 1 |
Table 3C: statutory scheme - eligible sales for older medicines and resulting scheme payments, excluding annual top-up payments
| Period | Aggregate statutory Scheme eligible sales: older medicines (£million) | Resulting aggregate statutory scheme payments: older medicines, excluding annual top-up payments (£million) |
|---|---|---|
| Jan to Mar 2025 | 51 | 5 |
| Apr to Jun 2025 | 54 | 6 |
Tables 3A, 3B and 3C notes:
- Tables 3A, 3B and 3C are derived from unaudited and audited statutory scheme sales reports. They set out aggregate information, showing eligible sales covered by the statutory scheme payment and the resulting payment.
- The term ‘eligible sales’ was implemented in the statutory scheme from 2024 onwards. For 2023, eligible sales are equivalent to net sales.
General notes
- The information in all tables is that held on the Department of Health and Social Care’s database at 20 August 2025.
- Totals may not sum due to rounding.
- All tables are subject to future correction such as where audited data replaces best available data and will be updated at each quarterly publication point to reflect the latest available information. The audit and reconciliation arrangements are set out in paragraphs 4.68 to 4.74 of the 2024 voluntary scheme. The statutory scheme audit requirements are set out at section 23 of the Branded Health Service Medicines (Costs) Regulations 2018.
- As set out in the scheme documentation, a 2-stage voluntary scheme-end reconciliation process to address any outstanding under or over payments will reflect the fact that final audited and de facto audited annual sales reports for 2027 and 2028 will not be received until 2029 and 2030, at the earliest, respectively. It will also account for any remaining rounding impact.
- Following the close of the third quarter of 2029, the department should have received audited or de facto audited returns for measured sales made in 2027, and updated data for measured sales made in 2028. This may be a mix of audited returns for scheme members with a financial year end of December, and unaudited returns for scheme members whose financial year end date differs from the calendar year end, or who have been delayed in providing their audited returns. This data will be used to calculate a revised payment percentage and corresponding payment for 2028. The revised payment percentage will be calculated to 2 decimal places. Any change arising in the payment due from scheme members following the revision of the 2028 payment percentage will be payable (or refundable) in the first quarter of 2030. This process will repeat following receipt of audited and de facto audited returns for measured sales made in 2028 a year later.